Lysozyme lactoperoxidase (Biotene) rinse was prescribed to BMS patients diagnosed with xerostomia (33) and reported a decrease in pain score of 1.7 units during short-term assessment (SMD −0.93, 95% CI −1.72 to −0.13) but no advantage over placebo was seen in long-term assessment (SMD −0.73, 95% CI −1.72 to 0.26). Here, LPO is linked to xerostomia.